118 related articles for article (PubMed ID: 33011530)
1. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract][Full Text] [Related]
2. Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Kim K; Kwon H; Barinka C; Motlova L; Nam S; Choi D; Ha H; Nam H; Son SH; Minn I; Pomper MG; Yang X; Kutil Z; Byun Y
J Med Chem; 2020 Mar; 63(6):3261-3273. PubMed ID: 32097010
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
4. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
5. Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives.
Young JD; Ma MT; Eykyn TR; Atkinson RA; Abbate V; Cilibrizzi A; Hider RC; Blower PJ
Bioorg Med Chem Lett; 2021 Jun; 42():128044. PubMed ID: 33865971
[TBL] [Abstract][Full Text] [Related]
6. Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity.
Novakova Z; Wozniak K; Jancarik A; Rais R; Wu Y; Pavlicek J; Ferraris D; Havlinova B; Ptacek J; Vavra J; Hin N; Rojas C; Majer P; Slusher BS; Tsukamoto T; Barinka C
J Med Chem; 2016 May; 59(10):4539-50. PubMed ID: 27074627
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.
Björklund C; Adolfsson H; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2010 Feb; 18(4):1711-23. PubMed ID: 20122837
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
9. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
10. Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): A molecular docking and molecular dynamics study.
Nikfarjam Z; Bavi O; Amini SK
Arch Biochem Biophys; 2021 Mar; 699():108747. PubMed ID: 33422503
[TBL] [Abstract][Full Text] [Related]
11. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies.
Wang H; Byun Y; Barinka C; Pullambhatla M; Bhang HE; Fox JJ; Lubkowski J; Mease RC; Pomper MG
Bioorg Med Chem Lett; 2010 Jan; 20(1):392-7. PubMed ID: 19897367
[TBL] [Abstract][Full Text] [Related]
12. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
[TBL] [Abstract][Full Text] [Related]
13. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Dannoon S; Ganguly T; Cahaya H; Geruntho JJ; Galliher MS; Beyer SK; Choy CJ; Hopkins MR; Regan M; Blecha JE; Skultetyova L; Drake CR; Jivan S; Barinka C; Jones EF; Berkman CE; VanBrocklin HF
J Med Chem; 2016 Jun; 59(12):5684-94. PubMed ID: 27228467
[TBL] [Abstract][Full Text] [Related]
14. (
Duan X; Liu F; Kwon H; Byun Y; Minn I; Cai X; Zhang J; Pomper MG; Yang Z; Xi Z; Yang X
J Med Chem; 2020 Apr; 63(7):3563-3576. PubMed ID: 32207938
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
16. Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Oliver AJ; Wiest O; Helquist P; Miller MJ; Tenniswood M
Bioorg Med Chem; 2003 Oct; 11(20):4455-61. PubMed ID: 13129582
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Pavlicek J; Ptacek J; Cerny J; Byun Y; Skultetyova L; Pomper MG; Lubkowski J; Barinka C
Bioorg Med Chem Lett; 2014 May; 24(10):2340-5. PubMed ID: 24731280
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
[TBL] [Abstract][Full Text] [Related]
19. 2-5A ligands--a new concept for the treatment of prostate cancer.
Cramer H; Okicki JR; Rho T; Wang X; Silverman RH; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1471-7. PubMed ID: 18066809
[TBL] [Abstract][Full Text] [Related]
20. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
